Global HTA Assessments of Ultra-Orphan Products- A Case Study Of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase)
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.1098
https://www.valueinhealthjournal.com/article/S1098-3015(14)03028-9/fulltext
Title :
Global HTA Assessments of Ultra-Orphan Products- A Case Study Of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)03028-9&doi=10.1016/j.jval.2014.08.1098
First page :
A431
Section Title :
Health Care Use and Policy Studies
Open access? :
No
Section Order :
600